SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: farkarooski who wrote (192)1/22/2003 2:30:13 PM
From: scion  Read Replies (2) of 250
 
A story on the Business Sunday page about an AIDS vaccine made some incorrect references to a clinical trial. A spokesman for VaxGen, a California pharmaceutical company, said yesterday that company officials do not know the results of the clinical trial, which have not yet been unsealed. The story incorrectly stated that VaxGen executives said their AIDS vaccine offers protection to less than a third of those who received it. Additionally, VaxGen chief executive Lance Gordon's Jan. 8 statement to financial analysts did not include a reference to an infection rate within the clinical trials; Gordon's reference to 3 percent infection referred to the incidence rate among gay men in the United States. The numbers and locations of trial participants were understated: The trial involved 5,100 gay men in the United States, Canada, the Netherlands and Puerto Rico, and 300 women. Also, the company's stock price increase was misstated; it has nearly quadrupled in value since July.

newsday.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News